Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04824950
Other study ID # CHB20.03
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date March 22, 2021
Est. completion date March 1, 2028

Study information

Verified date March 2021
Source Centre Henri Becquerel
Contact VINCENT CAMUS, MD
Phone +33232082497
Email vincent.camus@chb.unicancer.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to compare the predictive value in terms of specificity of circulating tumor DNA (ctDNA) and positron emission computed tomography (PET-CT) after 2 cycles of chemotherapy (C2), on the probability of obtaining a metabolic complete response after 4 cycles of induction chemotherapy (C4) in patients with primary mediastinal large B cell lymphoma (PMBL) receiving standard R-CHOP14 or R-ACVBP.


Description:

The majority of studies with PMBL patients pinpoint the importance of being able to identify primary chemo refractory patients at an early stage, in order to be able to improve their prognosis. Indeed, a biomarker such as circulating tumor DNA (ctDNA) monitoring would be of great help to better assess the therapeutic response and offer an individualized care given the frequent positive residual uptake of the mediastinum at end of treatment. Indeed, ctDNA can be detected with Next-Generation Sequencing (NGS). The hypothesis of this study is that it would be helpful to prospectively compare the predictive value of ctDNA versus PET on the capacity to detect primary refractory patients after 2 or 4 cycles of first line chemotherapy. To date, there are no prospective studies reporting the evolution of the tumor clone under treatment or after obtaining complete remission in PMBL. The establishment of this prospective, multicenter, ambitious and original pilot project will make it possible to structure the analysis of tumor DNA circulating within these centers caring for patients with lymphomas within LYSA group. The notion of minimal residual disease (MRD) has shown its interest in follicular lymphomas and mantle cell lymphomas. The level of sensitivity of NGS-type approaches on the one hand and the informativeness of the recurrent mutations recently described on the other hand constitute two elements for reconsidering the problem of MRD in PMBLs. Molecular MRD by analysis of circulating tumor DNA could constitute a new marker for monitoring response to treatment in addition to PET-CT and be useful as a tool for non-invasive tumor sequencing at diagnosis and at relapse, in order to to determine the eligibility for possible targeted therapies (based on the inactivation of mutated genes) or immunotherapies. This study will evaluate the prognostic value of obtaining a quantified complete molecular response (RMC) by analysis of free circulating DNA (ctDNA) after 2 and 4 cycles of first-line chemotherapy (C2 and C4) for the treatment of PMBL, and that of positron emission computed tomography (PET) performed at the same time, on overall survival and progression-free survival. The investigators will describe 3 different populations of patients included in the study: 1. Patients with "negative" plasma DNA at diagnosis (defined by the absence of somatic mutation detectable at diagnosis by ctDNA analysis) 2. Patients with "positive" plasma DNA at diagnosis (defined by the presence of at least one somatic mutation detectable at diagnosis by ctDNA analysis) and whose plasma DNA becomes "negative" after 2 cycles of chemotherapy 3. Patients with "positive" plasma DNA and whose plasma DNA remains "positive" after 2 cycles of chemotherapy For these 3 patient profiles, we will perform comparisons, search for correlations with different variables and perform univariate and multivariate statistical analyzes.


Recruitment information / eligibility

Status Recruiting
Enrollment 87
Est. completion date March 1, 2028
Est. primary completion date March 1, 2028
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patient over 18 years of age, - Suffering from a diffuse primary B lymphoma of the mediastinum, newly diagnosed locally on a biopsy with anatomopathological analysis according to the recommendations of the WHO 2016 classification of hematological malignancies, - All stages (I-IV) - All IPI scores (0-5) - With mediastinal involvement, - Untreated (apart from emergency corticosteroid therapy less than 2mg/kg/day for 7 days), - Treatment with R-CHOP-14 or R-ACVBP with PET-CT guided strategy (delta SUVmax) to be initiated, - Tumor fixation above liver background on pre-treatment FDG PET/CT/CT (Deauville score =4), - Having signed the informed consent prior to any study procedure - Affiliated or beneficiary of a social protection plan. Exclusion Criteria: - Patient who has already started chemotherapy treatment, - Contraindication to FDG PET-CT, - No mediastinal involvement, - Positive HIV serology, - Positive hepatitis B or C serology with positive viral load, - Protected adult (under guardianship or curatorship), - Pregnant or breastfeeding women, - Patient unable to understand the study for any reason or to comply with the constraints of the trial (language, psychological, geographical problems, etc.).

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Circulating tumor DNA monitoring
Monitoring of circulating tumor DNA after 2 and 4 cycles of chemotherapy

Locations

Country Name City State
France Centre Hospitalier Lyon Sud Lyon
France Centre Henri Becquerel Rouen

Sponsors (1)

Lead Sponsor Collaborator
Centre Henri Becquerel

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Correlation between circulating tumoral DNA detection and complete molecular response specificity of ctDNA at Cycle 2 of chemotherapy on the prediction of achieving a complete metabolic response (determined by PET-CT scan) at cycle 4 of chemotherapy 4 months
Secondary Evaluation of complete metabolic response Proportion of patient in complete metabolic response at the end of first line treatment at the end of first line treatment
Secondary Evaluation of response Percentage of patients in complete metabolic response, partial metabolic response, stable disease or pregression after 4 cycles of chemotherapy At the end of 4 cycles of chemotherapy
Secondary Evaluation of response Percentage of patients in complete metabolic response, partial metabolic response, stable disease or pregression at the end of treatment At the end of treatment
Secondary overall survival Time between death and inclusion 3 years
Secondary Event free survival Lenght of time after the end of tratment and events like progression, lake of response, relapse of death whatever the cause 3 years
Secondary genic expression profile Next-Generation-sequencing on diagnostic biopsy 3 years
Secondary Genomic sequencing of circulating tumor DNA Determination of molecular profile and evaluation of pronostic impact 3 years
Secondary Correlation between Next-Generation-Sequencing on tumor and molecular profile obtained on circulating tumor DNA Comparison between the result of Next generation Sequencing and the molocular profile obtained on circulation tumor DNA of each patient 3 years
See also
  Status Clinical Trial Phase
Recruiting NCT04759586 - Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma Phase 3
Completed NCT00532259 - CT-011 MAb in DLBCL Patients Following ASCT Phase 2
Completed NCT01965119 - Pilot Study of Ruxolitinib in Relapsed or Refractory Hodgkin Lymphoma and Primary Mediastinal Large B-cell Lymphoma Phase 2
Completed NCT00001337 - Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma Phase 2
Recruiting NCT03346642 - Two Stage Study of Combination of Chemotherapy, SHR-1210 and/or Decitabine for Relapsed/Refractory PMBCLs Phase 1/Phase 2
Terminated NCT04358458 - First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas Phase 1/Phase 2
Completed NCT01897571 - Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL Phase 1/Phase 2
Completed NCT04833504 - Clinical Follow-up Study of CD19 CAR-T Expressing IL7 and CCL19 for Relapsed or Refractory B Cell Lymphoma
Not yet recruiting NCT06238648 - Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy Phase 2
Terminated NCT04187872 - LITT and Pembrolizumab in Recurrent Brain Metastasis Phase 1
Withdrawn NCT02653989 - Efficacy and Safety Study of MDV9300 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) Phase 2